R. Pieschl

发表

B‐973, a novel piperazine positive allosteric modulator of the &agr;7 nicotinic acetylcholine receptor

J. Macor, J. Herrington, M. Ahlijanian, 2017, European journal of pharmacology.

Mapping the central effects of (±)-ketamine and traxoprodil using pharmacological magnetic resonance imaging in awake rats

W. Hayes, R. Pieschl, L. Bristow, 2018, Journal of psychopharmacology.

Effect of acute NR2B antagonist treatment on long-term potentiation in the rat hippocampus

Laszlo Kiss, R. Pieschl, J. Graef, 2015, Brain Research.

Competitive blocking of salivary gland [18F]DCFPyL uptake via localized, retrograde ductal injection of non-radioactive DCFPyL: a preclinical study

P. Choyke, J. Chiorini, C. Zheng, 2021, EJNMMI Research.

Monoamine reuptake site occupancy of sibutramine: Relationship to antidepressant-like and thermogenic effects in rats.

R. Pieschl, K. Rohrbach, N. Lodge, 2014, European journal of pharmacology.

Inhibition of in vivo [(3)H]MK-801 binding by NMDA receptor open channel blockers and GluN2B antagonists in rats and mice.

R. Pieschl, L. Bristow, A. Fernandes, 2015, European journal of pharmacology.

GABA receptor-mediated inhibition of neuronal activity in rat SCN in vitro: pharmacology and influence of circadian phase.

F. Dudek, V. Gribkoff, R. Pieschl, 2003, Journal of neurophysiology.

A Reexamination of the Role of GABA in the Mammalian Suprachiasmatic Nucleus

C. Pennartz, G. Strecker, F. Dudek, 1999, Journal of Biological Rhythms.

Discovery of Indole- and Indazole-acylsulfonamides as Potent and Selective NaV1.7 Inhibitors for the Treatment of Pain.

N. Meanwell, J. Herrington, D. Post‐Munson, 2018, Journal of medicinal chemistry.

Targeted Disruption of the Mouse Mel1b Melatonin Receptor

V. Gribkoff, S. Reppert, D. Weaver, 2003, Molecular and Cellular Biology.

Molecular Dissection of Two Distinct Actions of Melatonin on the Suprachiasmatic Circadian Clock

V. Gribkoff, S. Reppert, D. Weaver, 1997, Neuron.

Inhibition of AAK1 Kinase as a Novel Therapeutic Approach to Treat Neuropathic Pain

Alan G. E. Wilson, G. Shankar, S. Mandlekar, 2016, The Journal of Pharmacology and Experimental Therapeutics.

Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels

Astrid A. Ortiz, P. Molinoff, V. Gribkoff, 2001, Nature Medicine.

The Novel, Nicotinic Alpha7 Receptor Partial Agonist, BMS-933043, Improves Cognition and Sensory Processing in Preclinical Models of Schizophrenia

J. Macor, Yulia Benitex, D. Post‐Munson, 2016, PloS one.

Effects of BMS‐902483, an &agr;7 nicotinic acetylcholine receptor partial agonist, on cognition and sensory gating in relation to receptor occupancy in rodents

Y. Asaka, J. Macor, J. Herrington, 2017, European journal of pharmacology.

Discovery and Optimization of Biaryl Alkyl Ethers as a Novel Class of Highly Selective, CNS-Penetrable, and Orally Active Adaptor Protein-2-Associated Kinase 1 (AAK1) Inhibitors for the Potential Treatment of Neuropathic Pain.

G. Shankar, J. Macor, C. Albright, 2022, Journal of medicinal chemistry.

Diminished responses to monoaminergic antidepressants but not ketamine in a mouse model for neuropsychiatric lupus

B. Srikumar, R. Pieschl, L. Bristow, 2018, Journal of psychopharmacology.

Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.

Andrea Mcclure, Ping Chen, N. Meanwell, 2017, Bioorganic & medicinal chemistry.

Discovery of (S)-1-((2',6-Bis(difluoromethyl)-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine (BMS-986176/LX-9211): A Highly Selective, CNS Penetrable, and Orally Active Adaptor Protein-2 Associated Kinase 1 Inhibitor in Clinical Trials for the Treatment of Neuropathic Pain.

Alan G. E. Wilson, G. Shankar, J. Macor, 2022, Journal of medicinal chemistry.

NK1 receptor antagonism lowers occupancy requirement for antidepressant-like effects of SSRIs in the Gerbil forced swim test

J. Macor, R. Pieschl, T. Molski, 2013, Neuropharmacology.

A Functional NaV1.7-NaVAb Chimera with a Reconstituted High-Affinity ProTx-II Binding Site

D. Langley, J. Herrington, M. Ahlijanian, 2017, Molecular Pharmacology.

Synthesis and KCNQ2 opener activity of N-(1-benzo[1,3]dioxol-5-yl-ethyl, N-[1-(2,3-dihydro-benzofuran-5-yl)-ethyl, and N-[1-(2,3-dihydro-1H-indol-5-yl)-ethyl acrylamides.

Qi Gao, Jie Chen, Huan He, 2004, Bioorganic & medicinal chemistry letters.

(S)-N-[1-(4-cyclopropylmethyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)-ethyl]-3-(2-fluoro-phenyl)-acrylamide is a potent and efficacious KCNQ2 opener which inhibits induced hyperexcitability of rat hippocampal neurons.

Qi Gao, Jie Chen, Huan He, 2004, Bioorganic & medicinal chemistry letters.

Characterization of the adrenocorticotrophic hormone - induced mouse model of resistance to antidepressant drug treatment

B. Srikumar, R. Pieschl, L. Bristow, 2017, Pharmacology Biochemistry and Behavior.

Ex vivo assessment of binding site occupancy of monoamine reuptake inhibitors: Methodology and biological significance

R. Pieschl, T. Molski, N. Lodge, 2008, Neuropharmacology.

NR2B Antagonist CP-101,606 Abolishes Pitch-Mediated Deviance Detection in Awake Rats

M. Ahlijanian, R. Pieschl, Yili Yang, 2014, Front. Psychiatry.

Synthesis and evaluation of candidate PET radioligands for corticotropin-releasing factor type-1 receptors.

M. Imaizumi, S. Zoghbi, V. Pike, 2014, Nuclear medicine and biology.

Design, optimization, and in vivo evaluation of a series of pyridine derivatives with dual NK1 antagonism and SERT inhibition for the treatment of depression.

J. Macor, R. Pieschl, M. Parker, 2013, Bioorganic & medicinal chemistry letters.

[3H]BMT-046091 a potent and selective radioligand to determine AAK1 distribution and target engagement

J. Macor, C. Albright, R. Pieschl, 2017, Neuropharmacology.

Inhibition of AAK 1 Kinase as a Novel Therapeutic Approach to Treat Neuropathic Pain s

Alan G. E. Wilson, Malley, G. Shankar, 2016 .

Development of New Benzenesulfonamides As Potent and Selective Nav1.7 Inhibitors for the Treatment of Pain.

N. Meanwell, J. Herrington, D. Post‐Munson, 2017, Journal of medicinal chemistry.

Discovery of new indole-based acylsulfonamide Nav1.7 inhibitors.

N. Meanwell, J. Herrington, R. Pieschl, 2019, Bioorganic & medicinal chemistry letters.

Discovery of morpholine-based aryl sulfonamides as Nav1.7 inhibitors.

Andrea Mcclure, N. Meanwell, J. Herrington, 2018, Bioorganic & Medicinal Chemistry Letters.